CAR T-Cell Therapy for Esophageal Cancer
Trial Summary
What is the purpose of this trial?
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.
Will I have to stop taking my current medications?
The trial requires that you complete any systemic therapy at least 7 days before leukapheresis, and immune checkpoint inhibitor therapy must be completed at least 14 days before leukapheresis. You should discuss your current medications with the study team to ensure compliance with these requirements.
What data supports the effectiveness of the treatment M28z1XXPD1DNR CAR for esophageal cancer?
Research shows that CAR-T cell therapy, which is a type of treatment that uses modified immune cells to target cancer, has been effective in reducing tumors in esophageal cancer models. Specifically, CAR-T cells targeting a protein called CD276 have shown promising results in killing cancer cells and shrinking tumors in studies with mice.12345
Is CAR T-Cell Therapy for Esophageal Cancer safe?
The safety of CAR T-Cell Therapy for esophageal cancer specifically isn't detailed, but similar treatments like PD-1 inhibitors have shown manageable safety profiles in esophageal cancer. In studies, serious side effects occurred in some patients, but no treatment-related deaths were reported, and overall safety was considered acceptable.678910
What makes the M28z1XXPD1DNR CAR treatment unique for esophageal cancer?
The M28z1XXPD1DNR CAR treatment is unique because it uses CAR-T cells, a type of cell-based immunotherapy, to target specific proteins on esophageal cancer cells, potentially improving the effectiveness of treatment for solid tumors like esophageal cancer, which traditionally have limited therapeutic options.25111213
Research Team
Geoffrey Y. Ku
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for individuals with certain types of cancer affecting the lining of organs, esophagus, or stomach. Participants must have T cells that can be collected and modified in a lab. Specific eligibility details are not provided but typically include factors like age, health status, and prior treatments.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Leukapheresis and CAR T-cell Modification
Participants undergo leukapheresis to collect T cells, which are then modified to become MSLN-targeted CAR T cells
Treatment
Participants receive MSLN-targeted CAR T-cell therapy administered through the peritoneal cavity
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of adverse events
Treatment Details
Interventions
- M28z1XXPD1DNR CAR (CAR T-cell Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Lisa M. DeAngelis
Memorial Sloan Kettering Cancer Center
Chief Medical Officer since 2021
MD from Columbia University
Selwyn M. Vickers
Memorial Sloan Kettering Cancer Center
Chief Executive Officer since 2022
MD from Johns Hopkins University